文献速递肾小球疾病遗传性与小管间质肾病

小鼠Alport综合征足细胞对AAV9体内转导易感

Mouse Alport podocytes are susceptible to AAV9 transduction in vivo.
PubMed 文献 · Kidney Int · 2025-11-01

本研究在X连锁Alport小鼠中验证足细胞对AAV9的体内转导易感性。静脉注射ssAAV9-CAG-tdTomato或scAAV9-CMV-Cre后两周,Alport足细胞转导效率1.8%至26%,且与白蛋白尿水平正相关;对照小鼠足细胞未被转导。提示Alport肾小球基底膜随成熟对AAV9通透,为基因治疗提供概念验证。

要点

  • Alport小鼠足细胞可被AAV9转导,效率1.8%–26%且与白蛋白尿正相关
  • 对照小鼠足细胞未被AAV9转导,提示GBM通透性改变是关键
  • 系膜细胞在对照和年轻Alport小鼠中均对AAV9中度易感

核心结论

  • Alport小鼠GBM随成熟对AAV9通透,使病毒到达并转导相当部分足细胞。
  • 该结果为未来用AAV9或其他载体对Alport综合征患者进行基因治疗提供概念验证。

研究设计与样本

  • 概念验证研究,向Col4a5-/y及Col4a5-/y;Ai14 Alport小鼠静脉注射ssAAV9-CAG-tdTomato或scAAV9-CMV-Cre。
  • 注射两周后取肾,以突触足蛋白为足细胞标志物,用荧光法量化足细胞转导效率。

主要发现

  • ssAAV9-CAG-tdTomato在对照小鼠未转导足细胞,在杂合雌性和半合子雄性Alport小鼠足细胞转导效率为1.8%至26%,与白蛋白尿水平正相关。
  • 更敏感的Ai14系统给予scAAV9-CMV-Cre后,同样观察到足细胞转导与白蛋白尿相关。
  • 部分小管细胞和系膜细胞也可被转导,前者见于Alport小鼠,后者见于Alport和对照小鼠。

临床怎么用

  • 提示AAV9介导的足细胞基因递送在Alport综合征中具有可行性,但尚需临床前优化与安全性验证。
  • 小鼠系膜细胞对AAV9中度易感,可用于研究系膜细胞生物学的基因递送策略。

局限性

  • 研究为小鼠概念验证,样本量、具体转导效率的影响因素及长期安全性未在摘要中报告。
  • 足细胞转导效率与白蛋白尿相关,提示GBM病变程度可能影响转导,但机制未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alport syndrome features a defective glomerular basement membrane (GBM) due to variants in COL4A3, COL4A4, and COL4A5. The most severe forms, which lack the GBM's collagen α3α4α5(IV) network, progress from hematuria in early childhood to proteinuria, chronic kidney disease, and kidney failure by the age of ∼30. As a monogenic disease without specific treatments, and with podocytes being the only glomerular cells that synthesize collagen α3α4α5(IV), the ability to efficiently deliver genes to Alport podocytes could open up new possibilities for treatment. METHODS: As a proof-of-concept study, we investigated whether podocytes in X-linked Alport mice were susceptible to transduction by adeno-associated virus (AAV)9. ssAAV9-CAG-tdTomato and scAAV9-CMV-Cre were intravenously injected into Col4a5-/y and Col4a5-/y; Ai14 (Cre-activatable tdTomato) Alport mice, respectively. The kidneys were collected two weeks later and subjected to quantification of podocyte transduction by fluorescence assays using synaptopodin as a podocyte marker. RESULTS: ssAAV9-CAG-tdTomato delivered to controls failed to transduce podocytes, but heterozygous female and hemizygous male Alport podocytes showed a range of transduction efficiencies, from 1.8% to 26%, which correlated positively with levels of albuminuria. Similar correlation between podocyte transduction and albuminuria was observed in the more sensitive Ai14 system with scAAV9-CMV-Cre administration. A subset of tubular and mesangial cells could also be transduced, the former in Alport mice and the latter in both Alport and control mice. CONCLUSIONS: The Alport GBM becomes leaky to AAV9 as mice mature, allowing viruses to reach and transduce a substantial subset of podocytes. This is promising for someday using AAV9 or other vehicles in gene therapy for patients with Alport syndrome. Interestingly, mesangial cells of control and young Alport mice were moderately susceptible to transduction, demonstrating that gene delivery to mesangial cells in mice is a viable approach for investigating mesangial cell biology in any context.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Lin MH, Omachi K, Begin JF, et al. Mouse Alport podocytes are susceptible to AAV9 transduction in vivo. Kidney Int. 2025. PMID: 41183732. doi:10.1016/j.kint.2025.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。